MedTrace Logo

Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults

NCT04417257 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 351

Last updated 2025-11-13

Study results available
· View outcomes & findings →

Summary

A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.

Conditions

  • COVID-19 Disease

Interventions

DRUG

LAU-7b

LAU-7b will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.

DRUG

Placebo oral capsule

Placebo will be administered orally once-a-day with the main meal of the day, if possible, for a total of up to 14 days.

Sponsors & Collaborators

  • Laurent Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Jean-Marie Houle, PhD · Laurent Pharmaceuticals Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-18
Primary Completion
2024-02-15
Completion
2024-05-30
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04417257 on ClinicalTrials.gov